Humalog (Insulin Lispro)

Humalog is prescribed for the management of diabetes mellitus where rapid reduction of blood glucose is required.

• To control post‑meal (prandial) hyperglycemia in adults with type 1 diabetes.
• To control post‑meal hyperglycemia in adults with type 2 diabetes when diet, exercise, and oral agents are insufficient.
• As part of an intensive insulin regimen combined with basal insulin for flexible dosing.
• For use in insulin pump therapy (continuous subcutaneous insulin infusion) when rapid‑acting insulin is needed.
• In hospital settings for rapid correction of elevated glucose during surgery or acute illness.

• Insulin lispro is a recombinant human insulin analog in which two amino acids are reversed, resulting in reduced self‑association and faster absorption after subcutaneous injection. The molecule binds to the α‑subunit of the insulin receptor on muscle, adipose, and hepatic cells, activating the intrinsic tyrosine kinase. This triggers downstream signaling (PI3K/Akt pathway) that promotes translocation of GLUT‑4 transporters to the cell surface, enhancing glucose uptake and suppressing hepatic glucose production.

Like other rapid‑acting insulins, Humalog may cause a range of adverse reactions, most of which are related to its glucose‑lowering action or to local injection site responses.

Common

• Mild hypoglycemia (low blood glucose) presenting as shakiness, sweating, or hunger.
• Injection‑site pain, redness, or swelling.
• Lipodystrophy (localized thickening or loss of subcutaneous fat) with repeated use.
• Transient nausea or headache.

Serious

• Severe hypoglycemia leading to loss of consciousness, seizures, or need for assistance.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Acute insulin resistance or ketoacidosis if insulin is omitted in insulin‑dependent patients.
• Persistent edema or weight gain due to fluid retention.

Healthcare providers consider several precautionary measures before initiating Humalog to ensure safe and effective use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Review patient’s history of hypoglycemia unawareness or severe episodes.
• Adjust dose when starting or stopping concomitant medications that affect glucose (e.g., steroids).
• Counsel pregnant or breastfeeding women, noting limited safety data.
• Advise patients to rotate injection sites to reduce lipodystrophy.
• Monitor blood glucose closely during periods of illness, surgery, or changes in diet/exercise.
• Ensure proper storage (refrigerated, protect from heat) to maintain potency.

Humalog can interact with other agents that influence blood glucose levels or insulin pharmacokinetics.

Avoid

• Concurrent use of other rapid‑acting insulins or high‑dose insulin mixtures without dose adjustment.
• Beta‑blockers in patients prone to hypoglycemia, as they may mask symptoms.
• MAO‑inhibitors combined with sympathomimetic agents that can cause unpredictable glucose swings.

Use with caution

• Oral antidiabetic drugs (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids or growth hormone therapy, which raise glucose and may require higher insulin doses.
• Alcohol consumption, especially on an empty stomach, which can potentiate hypoglycemia.